Globenewswire·2026-02-15 23:11Core Viewpoint - A class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. for allegedly providing misleading information regarding the efficacy of its drug setrusumab during clinical trials, leading to inflated stock prices for investors [1][5][6]. Group 1: Lawsuit Details - The class action lawsuit is on behalf of purchasers of Ultragenyx common stock between August 3, 2023, and December 26, 2025 [1]. - The lawsuit claims that Ultragenyx's management made overly positive statements about setrusumab's ability to reduce fracture rates in Osteogenesis Imperfecta patients while concealing material adverse facts [5][6]. - It is alleged that the Phase III studies were less likely to demonstrate the claimed efficacy than management suggested, resulting in investors purchasing shares at artificially inflated prices [6]. Group 2: Legal Representation - Investors who purchased Ultragenyx stock during the class period may be entitled to compensation without upfront costs through a contingency fee arrangement [2]. - To join the class action, investors can visit the provided link or contact the law firm directly for more information [3][7]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4].